News

Who We Are
09.05.2011

InCROM Group and HMR collaborate over bridging studies

HMR and InCROM have agreed to work together to provide a full service for clinical trials across all phases of drug development, especially in Japanese people, by using their respective resources in the UK, Japan and China.

InCROM Group is a Japanese-owned SMO/CRO with bases in Japan and China. InCROM does phase 1, 2 and 3 clinical trials in Japan, and phase 3 and 4 clinical trials in China. InCROM was one of the first companies to provide a commercial service for clinical trials in Japan, and the first to establish a dedicated hospital for clinical trials in that country.

HMR is a CRO that does phase 1 and early phase 2 trials in the UK. One of its specialist services is 'bridging studies' in healthy Japanese people living in the UK.


Back to list
National Training Awards ISO 9001 certified LSE Elite A proud member of UK BioIndustry Association one nucleus
certificate